Background
==========

Delayed graft function (DGF) is usually defined based on the need for dialysis during the first week after kidney transplantation; excluding dialysis for hyperkalemia in the first 24 hours. It is increasingly recognized as a serious complication of kidney transplantation that can adversely affect the survival of the graft and transplant recipients \[[@b1-medscimonit-23-5472],[@b2-medscimonit-23-5472]\]. According to one study, recipients who experienced DGF had a 41% greater risk of graft loss at a mean follow-up time of 3.2 years \[[@b3-medscimonit-23-5472]\]. DGF rates have been increasing in parallel with increased use of donation-after-circulatory-death (DCD) kidneys, therefore it is likely to remain a significant clinical challenge in terms of patient quality of life and long-term allograft survival \[[@b4-medscimonit-23-5472]\]. Accurate evaluation of allograft quality is essential for surgeons to give a short-term prognosis for recipients and allografts, and thereby determine the appropriate perioperative care. However, there are few biomarkers and evaluation parameters which are routinely applied in clinical practice.

Metabolomics entails studying the metabolite profiles of biological fluids and extracts from cell or tissue, and it has been extensively applied for diagnosis and evaluation of some human pathologies, such as cancer, diabetes, neurological conditions and heart disease \[[@b5-medscimonit-23-5472]--[@b8-medscimonit-23-5472]\]. Owing to developments in diagnostic instrumentation, many analytical methods are now available for detecting and quantifying metabolites; these include nuclear magnetic resonance (NMR), gas chromatography/mass spectrometry (GC/MS) and liquid chromatography/mass spectrometry (LC/MS). Metabolomic analysis using proton nuclear magnetic resonance (^1^H-NMR) has shown a high degree of reproducibility, and can non-destructively and non-selectively detect and quantify multiple classes of metabolites. It has therefore become a preferred platform for quantitative spectral acquisition and comprehensive profiling of proton-containing low-molecular-weight metabolites \[[@b9-medscimonit-23-5472]\].

In the present study, we collected perfusate samples from kidney allografts prior to transplantation, and used ^1^H-NMR-based metabolomic analysis of these to compare kidneys exhibiting DGF upon transplantation to those exhibiting immediate graft function (IGF; controls).

Material and Methods
====================

Ethics statement
----------------

The study protocol was in accordance with the ethical standards of the Declarations of Helsinki and Istanbul. Being limited to donations after circulatory death, the protocol of this study was approved by the local Ethics Committee of the First Affiliated Hospital of Nanjing Medical University, and written informed consent was obtained from all transplant recipients. None of the transplant donors were from a vulnerable population, and written informed consent were received from each of patients.

Sample collection
-----------------

Adult kidneys acquired by DCD and accepted for transplantation at the kidney transplantation center of the First Affiliated Hospital of Nanjing Medical University between October 2014 and June 2015 were included. All allografts arrived at our transplant center in static cold storage, and demographic and clinical data for the donors were recorded.

Graft perfusion was performed 30 min before the transplantation surgery, with 1 L of hypertonic citrate adenine II solution at 0--4°C and a perfusion pressure of 100 cm H~2~O. No additional oxygen or glutathione (GSH) was supplied. After repair of the allograft was completed, 15 ml of the perfusate was sampled from the first outflow of the allograft renal vein. After high-speed centrifugation at 3000 rpm for 10 min, the supernatant of the perfusate was transferred to a cryogenic vial and stored at −80°C for further experiments.

Sample preparation and ^1^H-NMR analysis
----------------------------------------

We centrifuged the perfusate samples at 12,000 rpm for 10 min prior to NMR analysis. Then, we mixed buffer solution and sodium 3-trimethylsilyl-(2,2,3,3-D4)propionate (150 μL; Sigma-Aldrich, MO, USA) in D~2~O with 300 μL of supernatant from each perfusate sample. Finally, we collected 550 μL aliquots from the mixtures and transferred into NMR tubes.

AV 500 MHz spectrometer (Bruker, MA, USA) was used to detect ^1^H-NMR spectra. A transverse relaxation-edited Carr-Purcell-Meiboom-Gill sequence \[90-(τ-180-τ)*n*-acquisition\] with a total spin echo delay (2*n*τ) of 10 ms was employed to decay broad signals. Then, ^1^H-NMR spectra were measured using the following parameters: spectral width, 7500 MHz; number of sampling points, 32 K; relaxation delay time, 2 s; scanning time, 128 s. Finally, we phased the baseline correction of the spectra manually using the TOPSPIN 3.0 package (Bruker Biospin, Germany). All ^1^H-NMR spectrograms were obtained from the same spectrometer.

Statistical analysis
--------------------

Based on shifts corrected by the TSP signal, the spectra of ^1^H-NMR were aligned into integrated segments with 0.005 ppm widths (4.25--4.7 and 4.73--5.28 ppm). Then, principle component analysis (PCA) and orthogonal partial least-squares discriminant analysis (OPLS-DA) were applied to determine differences in the metabolite patterns of these 2 perfusate groups. In addition, corresponding loading plots were used to provide variable quantities. Taking component indices of subjects in both groups as study factors, SPSS 13.0 was used to process general data (SPSS Inc., IL, USA). The measured data was presented as mean ± standard deviation (SD), and a *t*-test was conducted for inter-group comparison of individual metabolites. Statistically significant was identified when *P*\<0.05.

Results
=======

Demographic and clinical characteristics
----------------------------------------

The demographic and clinical characteristics of the subjects are summarized in [Table 1](#t1-medscimonit-23-5472){ref-type="table"}. In all, 36 subjects were included: 11 with allografts that showed DGF after kidney transplantation and 25 with allografts showing IGF. There were no significant differences in the characteristics of donors and recipients between the DGF and IGF groups.

Metabolite profiling
--------------------

Representative ^1^H-NMR spectra for perfusate samples from both groups are shown in [Figure 1](#f1-medscimonit-23-5472){ref-type="fig"}. We assigned and identified 37 metabolites, whose inter-group variation is presented in [Table 2](#t2-medscimonit-23-5472){ref-type="table"}.

[Figure 2A](#f2-medscimonit-23-5472){ref-type="fig"} shows an OPLS-DA score plot of the ^1^H-NMR data, which was used to distinguish between DGF and IGF samples. In the OPLS-DA score plot, each point identifies a sample and each cluster represents a corresponding metabolic pattern. Significant separation was found between DGF and IGF samples (R^2^Y=0.922; Q^2^=0.910). The color-coded plot corresponded with coefficient-loading values visualized the influence of each metabolite between the DGF and IGF groups ([Figure 2C](#f2-medscimonit-23-5472){ref-type="fig"}). Levels of metabolites with positive correlation coefficients were lower in the DGF group than in the IGF group, whereas those with negative correlation coefficients were higher in the DGF group. Combining the coefficient-loading plot and an S-plot from the OPLS-DA analysis ([Figure 2B](#f2-medscimonit-23-5472){ref-type="fig"}), we found that the levels of 4 metabolites, citrate, α-glucose, betaine and taurine, were significantly different between the 2 groups (p\<0.05; [Table 2](#t2-medscimonit-23-5472){ref-type="table"}).

Discussion
==========

DGF is strongly associated with an increased risk of allograft loss after renal transplantation. DGF is becoming increasingly important, as the number of patients awaiting kidney transplantations is growing and there has been a great rise in the rate of donations after circulatory death in recent years in China. The current literature does not contain adequate evidence to provide a comprehensive mechanism for the development of DGF after kidney transplantation. Changes in perfusate compositions during static cold storage (SCS) may represent ongoing cell processes, or products of metabolism or degradation, being released from the kidneys. Metabolic profiling has been used to determine biomarkers for drug safety and efficacy, as well as for disease diagnosis (10). In this study, we applied the ^1^H NMR-based approach to evaluate the perfusate of allografts with DGF, and found that 4 important endogenous metabolites, citrate, α-glucose, betaine and taurine, were significantly associated with the occurrence of DGF.

Ischemia-reperfusion (IR) injury, which is a multifactorial pathogenesis, plays a central role in the development of DGF in allografts \[[@b11-medscimonit-23-5472]\]. IR injury is attributed to several processes triggered by the initial deprivation of oxygen and nutrients, along with the concomitant accumulation of metabolic waste products. Further damage is then done as a result of reperfusion products \[[@b12-medscimonit-23-5472],[@b13-medscimonit-23-5472]\]. Similar to how gene and protein levels often correlate with the activity of specific biochemical pathways and mechanisms, metabolite levels often correlate with processes such as cell metabolism, tissue oxygenation and oxidative stress, as well as general homeostasis \[[@b14-medscimonit-23-5472]\]. When compared to those of the IGF group, the DGF perfusates showed a significant increase in their α-glucose concentrations. Since α-glucose is one of the main components of the total glucose content, we inferred that total glucose would also likely have increased in the DGF group; this would indicate more active glucose metabolism in the DGF allografts during SCS. A potential role for glucose metabolism in IR injury is suggested by the results of Chang et al. \[[@b15-medscimonit-23-5472]\], who found that Dapagliflozin, an antidiabetic inhibitor of sodium/glucose cotransporter 2 (SGLT2), could attenuate IR injury. Moreover, hyperglycemia has been shown to exacerbate kidney IR injury and accelerate renal dysfunction, with several molecular pathways being profoundly affected by the hyperglycemia that occurs prior to renal IR injury \[[@b16-medscimonit-23-5472],[@b17-medscimonit-23-5472]\]. However, in the absence of samples and clinical measures from the donors, it was impossible to determine whether the glucose increase was due to IR injury or a prior insult.

Along with increased α-glucose, we found that DGF perfusates exhibited significantly elevated citrate and reduced levels of taurine and betaine. This suggests notable IR injury in the more ischemically damaged DGF allografts. There is evidence that anoxia, ischemia and infarction can lead to rapid loss of high-energy phosphates and accumulation of hydrolysis products, such as citrate, lactate and β-hydroxybutyrate; thus, allografts with higher levels of citrate may have suffered greater IR injury and thus be more susceptible to the occurrence of DGF after transplantation \[[@b18-medscimonit-23-5472]--[@b20-medscimonit-23-5472]\].

Even more importantly, IR injury could significantly impact osmoregulation, as reflected by the altered levels of osmolytes, like taurine and betaine, that have been demonstrated in both the present study and in previous ones \[[@b21-medscimonit-23-5472],[@b22-medscimonit-23-5472]\]. Taurine is a ubiquitous free amino acid which is present in many tissues and is involved in various physiological processes, such as osmoregulation, antioxidant activity and hepatic detoxification \[[@b23-medscimonit-23-5472],[@b24-medscimonit-23-5472]\]. There is strong evidence that taurine benefits ischemic reperfused kidneys by exerting a number of cytoprotective effects, such as a purported antioxidant effect, membrane stabilization, cellular osmoregulation and antiapoptotic effects \[[@b25-medscimonit-23-5472],[@b26-medscimonit-23-5472]\]. In addition, taurine is known to be an important modulator and regulator of renal function, and it contributes to body-fluid and electrolyte homeostasis. This suggests a critical role for taurine in renal IR injury \[[@b27-medscimonit-23-5472],[@b28-medscimonit-23-5472]\]. Like to taurine, the most important physiological roles for betaine are as an osmolyte and a methyl donor \[[@b29-medscimonit-23-5472]\]. As an osmolyte, betaine protects cells, proteins, and enzymes from environmental stresses, such as high salinity, low water and oxidative attack \[[@b30-medscimonit-23-5472]\]. Numerous studies have demonstrated the protective role of betaine during IR injury \[[@b21-medscimonit-23-5472],[@b31-medscimonit-23-5472]--[@b33-medscimonit-23-5472]\]. In our study, the DGF allografts showed lower taurine and betaine levels, so they may have suffered IR injury due, at least in part, to the loss of taurine and betaine's protective effects.

In 2014, Guy et al. \[[@b34-medscimonit-23-5472]\] studied the metabolite profiles of perfusates from 26 cadaveric cases, during hypothermic machine perfusion (HMP) of cadaveric kidneys using NMR spectroscopy. Their results showed that glucose, inosine, leucine and gluconate were significantly different in DGF group, which differed from ours in that the DGF group exhibited significant decreases in glucose, inosine, leucine and gluconate. This discrepancy could be explained by a number of methodological differences between the studies, including the details of measurement instruments, the application of HMP and the use of different preservation solutions.

Although our metabolomic analysis achieved significant results, it had some limitations. First, during SCS and perfusion of the allografts, we applied a hypertonic citrate adenine (HC-A) II solution, which, in China, is the most widely used kidney-preservation solution. HC-A II provides similar efficacy and safety to classical HTK solutions \[[@b35-medscimonit-23-5472]\], but along with dihydrogen phosphate, hydroxide phosphate, adenine and mannitol, it contains citrate and is therefore a potential confounding factor for the elevated citrate we observed in the DGF perfusates. Second, our sample population was too small owing to the strict inclusion and exclusion criteria used. A large number of subjects were ruled out because of particular details relating to the donation; for example, the recipient exhibited acute rejection or the presence of panel reactive antibodies, the donor was a child, the donor had a viral infection or abnormal blood pressure, the donor had received excessive administration of nephrotoxic drugs. Owing to the small number of eligible subjects, we were unable to evaluate the predictive role of the altered metabolites in the diagnosis of DGF. Therefore, a prospective large-scale study is needed to confirm our conclusions.

Conclusions
===========

In summary, an integrated NMR-based analysis of perfusates during SCS was employed to obtain the metabolite profiles of DGF and IGF allografts. Metabolomic analysis revealed significant increases in α-glucose and citrate levels, and significant decreases in taurine and betaine levels. These metabolomic perturbations may prove useful in explaining the mechanisms of kidney IR injury and DGF. Due to some limitations, larger-scale prospective studies should be conducted to confirm our results and their diagnostic and prognostic power.
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![(**A, B**) Representative 500 MHz ^1^H-NMR spectra of perfusate samples obtained from renal allografts that exhibited either delayed or immediate function upon transplantation (DGF and IGF, respectively).](medscimonit-23-5472-g001){#f1-medscimonit-23-5472}

![Scores plot, S-plot, and color-coded loadings plot for orthogonal partial least-squares discriminant analysis (OPLS-DA) of ^1^H-NMR data from renal-allograft perfusates. (**A**) Scores plot where each point represents 1 perfusate sample. (**B**) S-plot of perfusate samples. (**C**) Color-coded loadings plot shows metabolites that differed between the delayed (DGF) and immediate (IGF) graft-function groups (red, higher concentration; blue, lower concentration).](medscimonit-23-5472-g002){#f2-medscimonit-23-5472}

###### 

Baseline charaterisctics of subjects included in this study.

                                         IGF group    DGF group    *P* value
  -------------------------------------- ------------ ------------ -----------
  Number                                 25           11           NS
  Donor information                                                
   Age (years, mean ± SD)                39.72±2.00   40.73±1.01   NS
   Male (%)                              92.00        90.91        NS
   Warm ischemia time (min, mean ±SD)    2.240±0.24   3.455±0.98   NS
   Cold ischemia time (hour, mean ±SD)   9.040±0.48   9.273±0.60   NS
  Causes of death                                                  NS
   Brain tumor                           1            1            
   Brain trauma                          20           9            
   Cerebral hemorrhage                   4            1            
  Recipient information                                            
   Age (years, mean ±SD)                 37.94±1.93   39.15±1.42   NS
   Male (%)                              60.00        54.55        NS
   PRA (%)                               0            0            --

IGF -- immediate graft function; DGF -- delayed graft dysfunction; NS -- not significant; SD -- standard deviation; PRA -- panel reactive antibody.

###### 

Metabolites detected in the perfute of IGF and DGF allograft.

  No.   Metabolites               Chemical shifts (ppm)               Changes in IGF group *vs.* DGF group
  ----- ------------------------- ----------------------------------- ----------------------------------------------------------
  1     Isoleucine                0.88--0.94                          --
  2     Leucine                   0.95--0.98                          --
  3     Valine                    0.99--1.02; 1.03--1.06              --
  4     3-hydroxybutyrate         1.19--1.23                          --
  5     Lactic acid               1.32--1.38; 4.11--4.14              Down
  6     Alanine                   1.46--1.52                          Dwon
  7     Acetate                   1.92--1.94                          Down
  8     NAG                       2.05--2.15                          --
  9     GSH                       2.2--2.25; 2.55--2.58; 4.56--4.60   Down
  10    Glutamate                 2.33--2.39                          Down
  11    Succinate                 2.41--2.42                          Down
  12    Citrate                   2.65--2.75                          Down[\*](#tfn3-medscimonit-23-5472){ref-type="table-fn"}
  13    Creatine                  3.03--3.04; 3.92--3.95              Down
  14    Ethanolamine              3.11--3.14                          Down
  15    O-Acetylcholine           3.20--3.23                          Down
  16    Taruine                   3.30--3.32; 3.40--3.45              Up[\*](#tfn3-medscimonit-23-5472){ref-type="table-fn"}
  17    β-glucose                 3.46--3.51                          Up
  18    Glycine                   3.50--3.60                          Up
  19    α-glucose                 3.60--3.88                          Down[\*](#tfn3-medscimonit-23-5472){ref-type="table-fn"}
  20    Bet                       3.87--3.90                          Up[\*](#tfn3-medscimonit-23-5472){ref-type="table-fn"}
  21    Glycolate                 3.91--3.92                          Up
  22    Isocitrate                4.01--4.05                          Up
  23    Myo-inositol              4.06--4.08                          Up
  24    O-Phosphoserine           4.08--4.10; 4.16--4.20              Up
  25    Unsaturated lipid         5.24--5.26                          Down
  26    UDP-galactose             5.62--5.70                          Up
  27    Uridine                   5.89--5.95; 7.87--7.91              Up
  28    Inosine                   6.09--6.12; 8.35--8.37              Up
  29    Sodium fumarate dibasic   6.52--6.54                          Up
  30    Tyrosine                  6.89--6.92; 7.18--7.28              Up
  31    Histamine                 7.10--7.13                          Up
  32    Phenylalanine             7.30--7.46                          Down
  33    Uracil                    7.54--7.57                          Down
  34    Xanthine                  7.92--7.94                          Up
  35    Oxypurinol                8.20--8.23                          Down
  36    Niacinamide               8.26--8.28                          Up
  37    Formate                   8.45--8.46                          Down

DGF -- delayed graft function; IGF -- immediate graft function; NAG -- N-acetyl-beta-D-glucusamidase; GSH -- glutathione.

*P* value \<0.05;

*P* value \<0.01.
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